4-[(6,7-dimethoxy-4-quinolyl)oxy]-2,5-dimethylaniline | 286371-46-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[(6,7-dimethoxy-4-quinolyl)oxy]-2,5-dimethylaniline
• 英文别名: 4-((6,7-Dimethoxyquinolin-4-yl)oxy)-2,5-dimethylaniline；4-(6,7-dimethoxyquinolin-4-yl)oxy-2,5-dimethylaniline
• CAS: 286371-46-8
• 化学式: C₁₉H₂₀N₂O₃
• 分子量: 324.379
• InChiKey: RYOSIAALQNJYKP-UHFFFAOYSA-N

物化性质

• 沸点：
  488.5±45.0 °C(Predicted)
• 密度：
  1.200±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[(6,7-dimethoxy-4-quinolyl)oxy]-2,5-dimethylaniline 、 对甲氧基苯异氰酸酯 在 氯仿 、 乙醚 、 resultant precipitate 作用下， 以 氯仿 为溶剂， 反应 16.0h， 以to give 110 mg (yield 74%) of the title compound的产率得到N-{4-[(6,7-Dimethoxy-4-quinolyl)oxy]-2,5-dimethylphenyl}-N'-(4-methoxyphenyl)urea
  参考文献：
  名称：

  Quinoline derivatives and quinazoline derivatives

  摘要：

  本发明的目的是提供具有抗肿瘤活性且不改变细胞形态的化合物。本发明揭示了由式（I）表示的化合物及其药学上可接受的盐和溶剂，以及包括所述化合物的药物组合物：其中，X和Z各自独立地表示CH或N; R1至R3表示H，取代烷氧基，未取代烷氧基或类似物; R4表示H; R5至R8表示H，卤素，烷基，烷氧基，烷硫基，硝基或氨基，但要求R5至R8不同时表示H; R9和R10表示H，烷基或烷基羰基;以及R11表示烷基，烯基，炔基或芳基烷基。

  公开号：

  US06797823B1
• 作为产物：
  描述：

  4-氯 -6,7-二甲氧基喹啉 、 4-氨基-2,5-二甲基苯酚 在 二甲基亚砜 作用下， 以 水 为溶剂， 生成 4-[(6,7-dimethoxy-4-quinolyl)oxy]-2,5-dimethylaniline
  参考文献：
  名称：

  QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES

  摘要：

  公开号：

  EP1153920B1

文献信息

• Quinoline derivatives and quinazoline derivatives having azolyl group
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：US20030087907A1

  公开（公告）日：2003-05-08

  An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: 1 wherein X and Z represent CH or N; Y represents O or S; R 1 , R 2 , and R 3 represent H, alkoxy or the like; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, halogen, alkoxy or the like; R 9 and R 10 represent H, alkyl or the like; and R 11 represents optionally substituted azolyl.

  本发明的一个目的是提供具有强效抗肿瘤活性的化合物。根据本发明的化合物是由式（I）表示的化合物或其药学上可接受的盐或溶剂：其中X和Z表示CH或N；Y表示O或S；R1、R2和R3表示H、烷氧基或类似物；R4表示H；R5、R6、R7和R8表示H、卤素、烷氧基或类似物；R9和R10表示H、烷基或类似物；R11表示选择性取代的唑基。
• Quinoline and quinazoline derivatives and drugs containing the same
  申请人：——

  公开号：US20040132727A1

  公开（公告）日：2004-07-08

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: 1 wherein R 1 and R 2 represent hydrogen, alkyl or the like; R 3 , R 4 , R 5 and R 6 represent hydrogen, halogen, alkyl, alkoxy or the like; R 11 and R 12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R 3 , R 4 , R 5 and R 6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R 19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了一些化合物，可用于治疗由PDGF受体自磷酸化介导的疾病，特别是可抑制新内膜形成肥大的化合物。这些化合物由式（I）或其药理学上可接受的盐或溶剂表示：1其中R1和R2表示氢，烷基或类似物；R3、R4、R5和R6表示氢，卤素，烷基，烷氧基或类似物；R11和R12表示氢，烷基，烷基羰基或类似物；而A表示公式（i）到（x）中的任意一个，但其中R3、R4、R5和R6表示氢，A表示组（v）其中u为0（零）且R19表示苯基，可选地被卤素，烷基或烷氧基取代的化合物被排除。
• Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
  申请人：Kubo Kazuo

  公开号：US20060235033A1

  公开（公告）日：2006-10-19

  An objective of the present invention is to provide compounds which have inhibitory activity against autophosphorylation of macrophage colony-stimulating factor receptors. The compounds of the present invention are represented by formula (I) and salt and solvate thereof: wherein X represents CH or N; Z represents O or S; R 1 , R 2 , and R 3 represent H, optionally substituted alkoxy or the like; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, halogen, alkyl, alkoxy, trifluoromethyl or the like; R 9 and R 10 represent H, alkyl or the like; and any one of R 11 and R 12 represents H with the other representing alkyl and R 13 represents an optionally substituted carbocyclic or heterocyclic ring or the like, or R 11 represents H and R 12 and R 13 combine together to form a bicyclic carbocyclic ring.

  本发明的目标是提供具有抑制巨噬细胞集落刺激因子受体自磷酸化活性的化合物。本发明的化合物由式（I）及其盐和溶剂化物表示：其中X表示CH或N；Z表示O或S；R1、R2和R3表示H、可选地取代的烷氧基或类似物；R4表示H；R5、R6、R7和R8表示H、卤素、烷基、烷氧基、三氟甲基或类似物；R9和R10表示H、烷基或类似物；R11和R12中的任意一个表示H，另一个表示烷基，R13表示可选地取代的碳环或杂环环或类似物，或R11表示H，R12和R13结合形成双环碳环。
• QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME
  申请人：Fujiwara Yasunari

  公开号：US20080312221A1

  公开（公告）日：2008-12-18

  An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X=CH or N; Z=O or S; L=O or S; M=CR 10 R 11 , wherein R 10 and R 11 =H, alkyl, or alkoxy, NR 12 wherein R 12 =H or alkyl; R 1 , R 2 , and R 3 =H or optionally substituted alkoxy; R 4 =H; R 5-8 =H, halogen, alkoxy or the like; and R 9 =alkyl optionally substituted by —R 14 , -T-R 15 , or —NR 16 R 17 wherein T=O, S, or NH; R 14 =an optionally substituted carbocyclic or heterocyclic ring; and R 15-17 =alkyl or an optionally substituted carbocyclic or heterocyclic ring, or —NR 18 R 19 wherein R 18 and R 19 =H, optionally substituted alkyl, or an optionally substituted carbocylic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.

  本发明的目标是提供具有强效抗肿瘤活性的化合物。本发明的化合物由公式（I）或其药学上可接受的盐或溶剂表示：其中X = CH或N; Z = O或S; L = O或S; M = CR10R11，其中R10和R11 = H，烷基或烷氧基，NR12其中R12 = H或烷基; R1，R2和R3 = H或可选取代的烷氧基; R4 = H; R5-8 = H，卤素，烷氧基或类似物; R9 = 烷基，可选地被-R14，-T-R15或-NR16R17取代，其中T = O，S或NH; R14 = 可选取代的碳环或杂环; R15-17 = 烷基或可选取代的碳环或杂环，或-NR18R19其中R18和R19 = H，可选取代的烷基，或可选取代的碳环或杂环。
• NITROGEN-CONTAINING AROMATIC HETEROCYCLIC DERIVATIVE
  申请人：Furuta Takayuki

  公开号：US20130225581A1

  公开（公告）日：2013-08-29

  The present invention provides a nitrogen-containing aromatic heterocyclic derivative represented by formula (I): [wherein W represents CR 3 (wherein R 3 represents a hydrogen atom or the like) or the like, R 4 represents a hydrogen atom or the like, R 5 represents a hydrogen atom or the like, R 9 represents substituted imidazolyl, R 12 and R 13 may be the same or different, each represent a hydrogen atom or the like, R 22 and R 23 may be the same or different, each represent a hydrogen atom or the like, R 24 represents a hydrogen atom or the like, Y represents C—R 25 (wherein R 25 represents a hydrogen atom or the like) or the like] or a pharmaceutically acceptable salt thereof and a FGFR inhibitor comprising, as an active ingredient, the nitrogen-containing aromatic heterocyclic derivative or the pharmaceutically acceptable salt thereof, or the like.

  本发明提供一种由式(I)表示的含氮芳杂环衍生物：[其中W代表CR3（其中R3代表氢原子或类似物）或类似物，R4代表氢原子或类似物，R5代表氢原子或类似物，R9代表取代咪唑基，R12和R13可以相同也可以不同，每个代表氢原子或类似物，R22和R23可以相同也可以不同，每个代表氢原子或类似物，R24代表氢原子或类似物，Y代表C-R25（其中R25代表氢原子或类似物）或类似物]或其药学上可接受的盐，以及一种包含上述含氮芳杂环衍生物或其药学上可接受的盐作为活性成分的FGFR抑制剂，或类似物。